Daiichi Sankyo and Lilly continue talks with FDA re Prasugrel NDA

Daiichi Sankyo and Lilly are continuing to have discussions with the FDA regarding the review of the NDA for Prasugrel

Glenmark/Lilly suspend trials with TRPV1 antagonist GRC 6211 in OA

Glenmark and Lilly have announced they have suspended further clinical development for TRPV1 antagonist GRC 6211 in Osteoarthritis pain.

Lilly Launch new Forteo Delivery device

Eli Lilly have launhed a new, simpler-to-use FORTEO Delivery Device is available for patient use in the United States.

CHMP recommends approval of olanzapine LAI for maintenance therapy in schizophrenai

The CHMP has recommended European approval of Olanzapine Long-acting Injection (Zypadhera) for maintenance treatment of patients with schizophrenia

FDA extends prasugrel review period

The FDA has extended the review period for the prasugrel for the treatment of patients with acute coronary syndromes. The drug, codeveloped by Daiichi Sankyo and Lilly was initially granted priority review. The new FDA action date is September 26, 2008.

Lillys long acting injection olanzapine shows similar profile to Zyprexa

Data prsented at the Schizophrenia International Research Society meeting show Lilly’s long acting injection (LAI) formulation of olanzapine to demonstrate similar efficacy and safety to Zyprexa.

Lilly license TransPharmas transdermal Parathyroid Hormone

Lilly have licensed TransPharma’s Trandermal Parathyroid Hormone (hPTH (1-34)) for the treatment of Osteoporosis. The product is currently in Phase II clinical trials. Lilly will initially pay a $35 million upfront payment, to be followed by development and sales milestones and royalties on sales if the drug is marketed

Exenatide improves glycemic control in Type 2 Diabetes at one year

Data presented at ADA show that Amylin Pharmaceutical’s GLP-1 analog Exenatide continues to improve glucose control at one year in type 2 diabetes patients.